OBI Pharma, Inc.

Global Innovator in Immuno-Oncology and Targeted Cancer Therapies

Advancing in the Clinic!

Celeste Chuang, DPhil

QIC Healthcare Forum
14-18 Feb 2022

OBI PHARMA 台灣浩鼎

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements.**

Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc.

OBI PHARMA 台灣浩鼎

Agenda

1. **Company Introduction**
2. **Globo Series Science Leadership *Globo H***
   - **Novel I-O Pipeline**
3. **AKR1C3 Science Leadership**
   - **Novel Pro-drug**
4. **Key Milestones and Inflection Points**

OBI Pharma, Inc. (TPEx: 4174.TWO)

www.obipharma.com

Founded:	**April 29, 2002**
IPO on TPEx:	**March 23, 2015**
Market Cap 11 Jan, ’22:	**~US$ 900M (~NT$ 25B)**
Fund Raised at IPO:	**~US$ 200M (~NT$ 6.2B)**
Net Cash on Hand:	**~US$ 50M**
Employees:	**120**



OBI data on file

OBI Pharma Affiliated Enterprises (2022)
Equity investments (%)



Experienced Global Management Team

Michael Chang, PhD
Chairman & CEO

OPTIMER · MSD · RHÔNE-POULENC · PHARMANEX

Kevin Poulos
Chief Commercial Officer

OPTIMER · Wyeth · RHÔNE-POULENC · SmithKline Beecham

Tillman Pearce, MD
Chief Medical Officer

SANOFI · KALOBIOS · NOVARTIS · THRESHOLD PHARMACEUTICALS

Frank Chen
Chief Financial Officer

RUENTEX

Ming-Tain Lai, PhD
Chief Science Officer

MSD

Mitch Che
Chief Operating Officer

OPTIMER · AT&T · bp

David Hallinan, PhD
VP Regulatory Affairs

parexel · IDENIX

OBI PHARMA 台灣浩鼎

OBI Pharma Has Evolved Into an Oncology Company With a Diversified Portfolio of Novel Therapies

TARGETS: Globo H (+), SSEA-4 (+), AKR1C3 (+) Tumors

mAb: monoclonal antibodies ADC: Antibody Drug Conjugates BiAb: Bi-specific antibodies CAR-T: Chimeric Antigen Receptor T cell

OBI PHARMA 台灣浩鼎

Agenda

1. Company Introduction
2. Globo Series Science Leadership *Globo H*
   - Novel I-O Pipeline
3. AKR1C3 Science Leadership
   - Novel Pro-drug
4. Key Milestones and Inflection Points

Functions of Glycosphingolipids (GSLs)



A
Including and excluding proteins from microdomains

B
Several receptors can be directly regulated by GSLs present in the cell membrane

C
Crosslinking of several GSLs can induce signaling across the membrane

D
Interacting with glycans or with proteins on other cells, contributing to cell-cell recognition and adhesion

Zhang T, et al. *Front Immunol.* 2019 Jan 29;10:90. doi: 10.3389/fimmu.2019.00090. eCollection 2019.

OBI PHARMA 台灣浩鼎

Glycans, Glycosphingolipids and Cancer

- Glycans and glycosphingolipids (GSLs) play a crucial role in tumor progression
- Aberrant glycosylation is a hallmark of cancer cells
- GSLs are glycans conjugated to a lipid (ceramide) core
- Globo series is a unique class of GSLs involved in early embryogenesis and tumor development



OBI data on file

Potential Roles of Globo H in Immunosuppression, Angiogenesis, and Cancer Cell Survival Signaling



1Tsai YC, *et al*. *J Cancer Sci Ther* 2013;5:264-270
2Cheng JY, *et al*. *Cancer Res* 2014;74:6856-6686
3Chuang PK, *et al. PNAS* 2019;116:3518-3523

OBI PHARMA 台灣浩鼎

High Globo H Expression in Common Cancers



Cancer	# Evaluable Specimens	# H-score ≥100	Prevalence at H-score ≥100
Pancreatic	72	36	**50.0%**
Esophageal	64	11	**17.2%**
Gastric	73	18	**24.7%**
Breast	131	17	**13.0%**
Lung	77	8	**10.4%**
Colon	75	12	**16.0%**

OBI's Globo H Expression Assay (NeoGenomics)
IDE-Approved by FDA

Resections + TMAs + 822-001 Samples. TMA: tissue microarray. Red bar: median score. OBI Data on File.

OBI PHARMA 台灣浩鼎

OBI Pharma's First-in-Class Cancer Pipeline
Stage of Development

PRODUCT	TYPE	TARGET	CANCER	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Adagloxad Simolenin	Vaccine	Globo H	Breast (TNBC)	GLORIA Global Phase 3 TNBC Study			
OBI-888	mAb	Globo H	Multiple Cancers				
OBI-999	ADC	Globo H	Multiple Cancers				
OBI-833	Vaccine	Globo H	Multiple Cancers				
OBI-3424	Prodrug	AKR1C3	Multiple Cancers				
OBI-866	Vaccine	SSEA-4	Multiple Cancers				

OBI Data on File.

Adagloxad Simolenin

First-in-Class Active Immunotherapy Stimulating anti-Globo H Antibodies

OBI PHARMA 台灣浩鼎

Adagolaxad Simolenin (OBI-822) + OBI-821

Adagloxad Simolenin (OBI-822) + the saponin adjuvant OBI-821 is a therapeutic vaccine targeting Globo H ceramide in a variety of epithelial tumors



+

Adagloxad Simolenin (OBI-822)

Comprises a fully synthetic tumor antigen (Globo H) conjugated to a protein carrier (KLH)

Potent Adjuvant (OBI-821)

Saponin-based adjuvant

Induces humoral and cell-mediated immune responses

OBI data on file

GLORIA

Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple-Negative Breast Cancer

Clinicaltrials.gov. Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC NCT03562637

OBI PHARMA 台灣浩鼎

Globo H Expression in Triple Negative Breast Cancer



White 57-year-old female with infiltrating ductal carcinoma
H-score = 300



White 59-year-old female with papillary carcinoma
H-score = 185

GH expression level was assessed, and results are presented using an H-score system (0 to 300)

H-score = (% of weak intensity x 1) + (% of moderate intensity x 2) + (% of strong intensity x 3)

OBI data on file

OBI PHARMA 台灣浩鼎

GLORIA Phase 3 TNBC Study Design



Key Eligibility Criteria

- Histologically documented TNBC (ER/PR ≤5% cells)
- High risk defined as:
  - ≥1 cm residual primary or ≥1 residual axillary node after adequate neoadjuvant chemotherapy
    or
  - Pathological Stage IIB or III disease treated with adequate adjuvant chemotherapy alone
- Received ≥4 cycles of standard taxane- and/or anthracycline-based chemotherapy

Primary Endpoint: IDFS

- 187 events required (3-year IDFS HR 0.66)
- 80% power; two-sided alpha 0.05

OBI PHARMA 台灣浩鼎

GLORIA Phase 3 TNBC Study Objectives

Primary Objective

- To determine the effect of adagloxad simolenin (AS) treatment on improving IDFS in the study population

Secondary Objectives

- To determine the impact of AS treatment in the study population, on:
  - Overall Survival (OS)
  - Quality of Life (QoL)
  - Breast cancer-free interval (BCFI)
  - Distant disease-free survival (DDFS)
- To determine safety and tolerability of AS in the study population

Exploratory Objectives

- To explore the association between the anti-Globo H antibody response to AS and IDFS and OS
- To evaluate the impact of tumor expression of Globo H on IDFS and OS
- To identify patient baseline characteristics and demographics that may be predictive of treatment outcomes with AS
- To explore the association between baseline characteristics, including tumor pathological, molecular and immune features, and tumor expression of Globo H

OBI PHARMA 台灣浩鼎

Adagloxad Simolenin Global Phase 3 Trial Investigator Site Locations

OBI data on file

OBI-833

Cancer Vaccine Targeting Tumor Expression of Globo H

OBI-833

OBI-833 + the saponin adjuvant OBI-821 is a therapeutic vaccine targeting Globo H ceramide in a variety of epithelial tumors

Innovative Glycoprotein



+

Saponin adjuvant OBI-821



OBI-833

Comprises a fully synthetic tumor antigen (Globo H) conjugated to a protein carrier (CRM-197)

OBI-821

Induces humoral and cell-mediated immune responses

OBI data on file

Encouraging Phase 1 NSCLC cohort expansion results

- OBI-833 demonstrated a favorable safety profile.
- OBI-833 elicited a **beneficial immune response** in NSCLC patients and rendered some TKI-treated patients **durable stable disease status**.
- The median progression-free survival was 38.1 weeks.
- 11 of the 14 patients were **co-treated with an EGFR TKI** in the study. Eight of them remained in stable disease status for over 6 months.
- Two patients were treated with OBI-833 for **over 2 years**; one of the patient showed tumor size reduction by 27% after 16 months of OBI-833 treatment.
- 50% patients had high Globo H (H Score > 100) expression.
- Phase 2 study in preparation.

OBI data on file

OBI-833 P1 study published at ESMO

A Phase 1 Cohort Expansion Trial of OBI-833 in Non-Small Cell Lung Cancer Patients

Ching-Liang Ho[1], Kang-Yun Lee[2], Her-Shyong Shiah[3], Chia-Chi Lin[4], Chien-Chih Ou[5], Chen-En Tsai[5], Pan-Chyr Yang[7]

[1] Division of Hematology/Oncology, Try-Service General Hospital, National Defense Medical Center, Taipei, Taiwan [2] Division of Thoracic Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan [3] Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan
[4] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan [5] Department of Clinical Development, OBI Pharma, Taipei, Taiwan [6] Department of Medical Affairs and Clinical Development, OBI Pharma, Taipei, Taiwan [7] Department of Internal Medicine, National Taiwan University, Taipei, Taiwan

Introduction

- Globo H, a glycan initially isolated from the MCF-7 breast cancer cell line, is overexpressed in a variety of epithelial cell tumors such as colon, ovarian, gastric, pancreatic, lung, prostate, and breast cancers, and has limited expression in normal tissue.
- Experimental data suggest that Globo H promotes immunosuppression, tumor survival signaling, and angiogenesis.
- Globo H expression in tumor cells and its function as a potential immune checkpoint make it a target for immunotherapy.
- OBI-833, a novel cancer active immunotherapy, comprises of a synthetic Globo H conjugated with a recombinant CRM 197.

Background

- Lung cancer is the leading cause of cancer-related deaths worldwide (Jemal et al, 2009) and non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers (Sher et al, 2008; Wang et al, 2011).
- Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in NSCLC, particularly in tumors of adenocarcinoma histology. *EGFR* mutation frequency was 47.9% in Asian patients, as compared with 19.2% in Western patients.
- Globo H is highly expressed in epithelial cancers such as lung cancer, breast cancer, prostate cancer (Zhang et al, 1997b) and pancreatic, gastric and esophageal cancer (AACR; 2020. Abstract nr 2946)
- OBI-833 is a novel cancer vaccine targeting Globo H. Results of the dose-escalation trial showed a favorable safety profile and supported the cohort expansion trial in NSCLC patients at a dose of 30 μg.
- Patients with Globo H-positive metastatic NSCLC who had achieved stable disease (SD) or partial response (PR) after at least one regimen of anticancer therapy were enrolled. For patients who were on the targeted therapy, OBI-833 was added to their ongoing therapies. Humoral immune responses and relevant tumor biomarkers were monitored.

Disposition

	Number of Patients Cohort Expansion
Screened	24
Enrolled Population	14
Safety Population	14
	Number of Study Discontinuation
Disease Progression	11
SUSAR*	1
Withdrawal of Consent	0

*Grade 4 acute pancreatitis, possibly related

Adverse Events

- As of June 2020, a total of 126 AEs were reported, of which 79 were considered as treatment related AEs. Most of them were injection site reactions. Among the 3 reported SAEs, one was treatment-related, which was Grade 4 acute pancreatitis, and two were non-treatment related.
- Injection site reactions were less than Grade 2, occurred on the day of injection, recovered within 2-3 days without medical treatment, and usually recurred after each subsequent injection.

Summary of Serious Adverse Events

Subject ID	SAE (Preferred Term)	Severity	Relationship
034-005	Ascites	Grade 3	Not-related
034-008	Pneumonia	Grade 5	Not-related
034-006	Acute pancreatitis	Grade 4	Possibly-related

Globo H Expression in 24 Screened Subjects



Antibody Responses



93% and 64% of patients showed positive blood anti-Globo H IgM and IgG results, respectively. The positivity was defined as the anti-Globo H IgM or IgG concentration ≥ 3 μg/mL at least once during the study period.

Tumor Responses



Swimmer Plot of Time to Progression

Median PFS was 31 weeks (range, 3–108). Six of the 11 EGFR TKI-treated patients had SD for over six months. One patient has been treated for more than two years and his treatment is still ongoing. Of note, one patient's tumor size had reduced by 27% after 16 months of OBI-833 treatment.

Conclusions

- OBI-833 can elicit a beneficial immune response in NSCLC patients and rendered durable stable disease status for some TKI-treated patients.
- Further development of OBI-833 in *EGFR*-mutated NSCLC patients to assess the potential benefits of combination therapy of OBI-833 with TKIs is ongoing.

台灣浩鼎

OBI-888

First-in-Class Monoclonal Antibody Targeting Tumor Expression of Globo H

OBI-888 Inhibits Tumor Growth in 5 Cancer Xenograft Models

CANCER TYPE	TUMOR MODEL	DOSES (mg/kg)	TREATMENT DURATION	TGI AT TOP DOSE TESTED, %
Breast	**MCF7**	1, 3, 10	Q2W x 6	**85%**
Breast	**HCC-1428**	3, 10, 30	Q2W x 6	**55%**
Pancreatic	**HPAC**	5, 20, 80	Q2W x 5	**47%**
Colorectal	**SW480**	100	Q2W x 4	**49%**
Lung	**NCI-H526**	10, 30, 100	Q2W x 5	**43%**

Q2W, every 2 weeks; TGI, tumor growth inhibition.
Chen, YC *et al. AACR 2019*. Abstract No. 544.
OBI Data on File.

OBI PHARMA 台灣浩鼎

OBI 888-001 Two-Part Phase 1 Study
Part 1: Dose Escalation

Dose Escalation (3+3)



Results

- No drug-related SAEs
- No DLTs at 20 mg/kg
- OBI-888 was well tolerated

Endpoints: Safety, efficacy, PK/ADA, Tumor and CTC exploratory biomarkers

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center

* Number of patients who completed the 4-week DLT assessment

A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT03573544

OBI PHARMA 台灣浩鼎

Recruiting the Cohort Expansion Portion of the OBI-888-001 Phase 1/2 Study

- OBI-888 monotherapy at **20 mg/kg weekly**
- Advanced cancer; no effective SOC available; measurable disease; PS 0-1
- Patient tumor sample must have an **H score of ≥100** for Globo H in an **FDA IDE-approved assay** (NeoGenomics)
- H_0 5%; H_1 25%; alpha 0.05%; power 90%; ≥1/9; ≥4/30

(8) Stage 2 Study Centers

(5) United States: MDACC, West Clinic, Scripps, USC and Rutgers

(3) Taiwan: TVGH, CMUH and NCKUH

*The basket cohort includes all other epithelial cancers.
A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT03573544

OBI PHARMA 台灣浩鼎

OBI-999

Antibody-Drug Conjugate (ADC) Targeting Tumor Expression of Globo H

OBI-999 Targeting Tumor-Specific Globo H

Proprietary Novel Site-Specific Linker Technology ThioBridge®



Maintains the stability of the antibody and a consistent drug-to-antibody ratio (DAR)

Improved Homogeneity vs Adcetris



DAR4>95%



DAR2 & DAR4 (majority)

	OBI-999	Adcetris
Target / Linker / Payload	**Globo H Ab / Thiobrige / vc-PAB-MMAE**	**CD30 Ab / Maleimide / vc-MMAE**
Linker	**Thiobridge** (proprietary)	**Maleimide** (generic)
Conjugation technology	**Site specific**	**Random**

OBI data on file. ThioBridge® is the registered trademark of Abzena

OBI PHARMA 台灣浩鼎

OBI-999 Strong Anti-Tumor Effects in 4 Cancer Models

CANCER TYPE	TUMOR MODEL	TREATMENT DURATION	ANTI-TUMOR EFFECT AT TOP DOSE
Pancreatic	**HPAC**	QW x 4	**Tumor Free**
Gastric	**NCI-N87**	QW x 4	**Tumor Free** (achieved at both 3 and 10 mg/kg)
Lung PDX	**LU-01-0266**	QW x 4	**Tumor Free**
Breast	**MCF7**	QW x 6 or Q3W x 2	**Tumor Free**

PDX, patient-derived xenograft; TGI, tumor growth inhibition; QW, every week; Q3W, every 3 weeks.

Yang, MC *et al*. *AACR 2019*. Abstract No. 4814. OBI Data on File.

OBI PHARMA 台灣浩鼎

OBI-999 Strong tumor growth inhibition in NCI-N87 Gastric carcinoma xenograft

Globo H expression: 57%.



Orphan Drug Designation approved by US FDA

Apostolia Maria Tsimberidou et al. A Phase 1/2, Open-Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors. Poster # 387 ASCO20 Virtual Annual Meeting June 2020

OBI PHARMA 台灣浩鼎

Initiation Phase 2 portion of study November 2021

- Subject number: 3+3 design, up to 30 (sequential enrollment);
- Treatment cycle: 21-day cycle up to 35 cycles (approximately 2 years);
- SRC: review safety and PK data after each cohort completes the 1st cycle.
- Patient tumor sample must have an **H score of ≥100** for Globo H in an **FDA IDE-approved assay** (NeoGenomics)



- Primary objectives:
  - Safety and tolerability of OBI-999
  - MTD and PR2D
- Secondary objectives:
  - ORR, CBR, DOR, PFS
  - ADAs
  - PK
- Exploratory objectives:
  - Tumor Tissue Samples: Globo H testing

Apostolia Maria Tsimberidou et al. A Phase 1/2, Open-Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors. Poster # 387 ASCO20 Virtual Annual Meeting June 2020

OBI PHARMA 台灣浩鼎

Agenda

1. Company Introduction
2. Globo Series Science Leadership *Globo H*
   - Novel I-O Pipeline
3. **AKR1C3 Science Leadership**
   - **Novel Pro-drug**
4. Key Milestones and Inflection Points

OBI-3424

Small Molecule Prodrug Targeting Tumors Expressing the AKR1C3 Enzyme

OBI Pharma's First-in-Class Cancer Pipeline
Stage of Development

PRODUCT	TYPE	TARGET	CANCER	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Adagloxad Simolenin	Vaccine	Globo H	Breast (TNBC)	GLORIA Global Phase 3 TNBC Study			
OBI-888	mAb	Globo H					
OBI-999	ADC	Globo H	Multiple Cancers				
OBI-833	Vaccine	Globo H	Multiple Cancers				
OBI-3424	Prodrug	AKR1C3	Multiple Cancers				
OBI-866	Vaccine	SSEA-4	Multiple Cancers				

OBI Data on File.

The Prodrug OBI-3424 Is Converted to Active Drug in AKR1C3 Expressing Tumor Cells



Apostolia Maria Tsimberidou et al. A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC). Poster # 388 ASCO20 Virtual Annual Meeting

OBI PHARMA 台灣浩鼎

AKR1C3 Prevalence in 10 Cancer Types

Prevalence of H-score ≥135



Median	200	235	180	120	145	105	100	0	70	5	0	5	0	140	32.5	0	1.5	0	3
N	5	3	25	3	25	3	25	3	75	25	3	100	3	49	20	1	20	3	20
Prevalence* (%)	100	100	64	0	56	0	24	0	36	8	0	8	0	55	35	0	5	0	15

OBI Data on file. Immunohistochemistry (IHC) staining assay was used to survey the expression levels in various human tissue types.

OBI PHARMA 台灣浩鼎

OBI-3424 Tumor Inhibition in Orthotopic Xenograft Liver Cancer Animal Model

(1.25mg/kg and 2.5mg/kg)



Apostolia Maria Tsimberidou et al. A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC). Poster # 388 ASCO20 Virtual Annual Meeting

OBI PHARMA 台灣浩鼎

OBI-3424-001 Part 2 Cohort Expansion Initiated



MDACC, OSU, MSKCC, West, Scripps, Rutgers, USC, UCSF

Clinicaltrials.gov. This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. NCT03592264

OBI-3424 Potential Therapeutic Value in T-cell Acute Lymphoblastic Leukemia (T-ALL)

Translational Cancer Mechanisms and Therapy

Clinical Cancer Research

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Kathryn Evans[1], JianXin Duan[2], Tara Pritchard[1], Connor D. Jones[1], Lisa McDermott[1], Zhaohui Gu[3], Cara E. Toscan[1], Narimanne El-Zein[1], Chelsea Mayoh[1], Stephen W. Erickson[4], Yuelong Guo[4], Fanying Meng[2], Donald Jung[2], Komal S. Rathi[5], Kathryn G. Roberts[3], Charles G. Mullighan[3], Chi-Sheng Shia[6], Tillman Pearce[6], Beverly A. Teicher[7], Malcolm A. Smith[7], and Richard B. Lock[1]

Clin Cancer Res; 25(14) July 15, 2019

Significant Reduction in Leukemia Bone Marrow Infiltration With OBI-3424 in PDX Model (T-ALL 31)



"OBI-3424 is one of the most effective drugs we have ever tested against T-ALL in over 12 years of evaluating drugs at the Children's Cancer Institute using preclinical models of childhood ALL"

Prof Richard B. Lock
Head of the Leukemia Biology Program
Children's Cancer Institute in Australia

Data presented at the 2018 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract number: LB-B16. Clin Cancer Res April 23 2019 **DOI:** 10.1158/1078-0432.CCR-19-0551

OBI PHARMA 台灣浩鼎

OBI-3424 Phase 2 T-ALL Study sponsored by SWOG ongoing

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies | About Studies | Submit Studies | Resources | About Site | PRS Login

Home > Search Results > Study Record Detail

Save this study

Trial record **1 of 2** for: OBI-3424

Previous Study | Return to List | Next Study

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04315324

Recruitment Status : Recruiting
First Posted : March 19, 2020
Last Update Posted : January 7, 2021

See Contacts and Locations

Sponsor:
Southwest Oncology Group

Collaborator:
National Cancer Institute (NCI)

Information provided by (Responsible Party):
Southwest Oncology Group

Clinicaltrials.gov A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) NCT04315324

OBI PHARMA 台灣浩鼎

Agenda

1. Company Introduction
2. Globo Series Science Leadership *Globo H*
   - Novel I-O Pipeline
3. AKR1C3 Science Leadership
   - Novel Pro-drug
4. **Key Milestones and Inflection Points**

OBI PHARMA 台灣浩鼎

Globo H scientific posters presented at 2020 AACR



AACR American Association for Cancer Research

Tzer-Min Kuo, PhD, et. al., The role of Globo H in cancer cell survival Poster 2934/8. I-Ju Chen, PhD, et. al., The prevalence of Globo H in different tumor types: Breast, pancreatic, lung, gastric, colorectal, liver, and esophageal cancers Poster 2946/20. American Association of Cancer Research (AACR) Virtual Annual Meeting II from June 22–24, 2020.

OBI PHARMA 台灣浩鼎

OBI Trial-in-Progress Posters at 2020 ASCO Congress

Adagloxad Simolenin, OBI 999, OBI 3424

ASCO ANNUAL MEETING

A Phase 1/2, Open-Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors.

Apostolia Maria Tsimberidou[1], Jaffer A. Ajani[1], Pei Hsu[2], I-Ju Chen[2], Tillman E. Pearce[3]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX; [2]OBI Pharma Inc., Taipei City, Taiwan; [3]OBI Pharma USA, Inc., San Diego, CA

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage, Globo H-Positive, Triple-Negative Breast Cancer

Hope S. Rugo[1], Javier Cortes[2], Louis W. C. Chow[3], Peter A. Fasching[4], Pei Hsu[5], Chiun-Sheng Huang[6], Sung-Bae Kim[7], Yen-Shen Lu[6], Michelle E. Melisko[8], Rita Nanda[9], Priyanka Sharma[10], Richard B. Schwab[11], Binghe Xu[12], Tillman E. Pearce[13]

A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC)

Apostolia Maria Tsimberidou[1], Claire F. Verschraegen[2], Pei Hsu[3], Chun-Chung Wang[3], Tillman E. Pearce[4]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX; [2]The Ohio State University, Columbus, Ohio; [3]OBI Pharma Inc., Taipei City, Taiwan; [4]OBI Pharma USA, Inc., San Diego, CA

OBI Research Posters at 2021 AACR Conference



Projected Phase 1-2 Clinical Data in 2021-22
1st-in-class Oncology products



OBI Data on File * Projected.

OBI PHARMA 台灣浩鼎

Thank You

For further information please contact:

Celeste Chuang, DPhil
Sr Manager Business Development
cchuang@obipharma.com
http://www.obipharma.com/